HLS Therapeutics Inc.
4.33CAD
+0.1800 (+4.34%)
Not enough data yet
A reading needs 5 members, each at least 14 days old with a track record on this site (simulated portfolios and calls), who shared a take in the last 30 days; 2 of them need a strong record.
Sign in to share your take on HLS.TO.
Buy HLS.TO at 3.75 CAD
Imported from Value Investors Club — ChapterTwelveCapital
Consensus EPS on the street’s adjusted basis, not the filed GAAP figure — which is why the actuals here can differ from the income statement.
| Period | Consensus EPS | 90 days ago | Revisions up (30d) | Revisions down (30d) |
|---|---|---|---|---|
| Current quarter | -$0.08▼ | -$0.06 | 0 | 1 |
| Next quarter | -$0.04▼ | -$0.03 | 1 | 0 |
| Current year | -$0.21▼ | -$0.2 | 1 | 0 |
| Next year | -$0.07▼ | -$0.03 | 0 | 0 |
Beat in 2 of the last 4
| Quarter | Estimate | Actual | Surprise |
|---|---|---|---|
| 2026-06-30 | -$0.08 | -$0.03 | +0.05 (+62.5%) |
| 2026-03-31 | -$0.12 | -$0.07 | +0.05 (+41.7%) |
| 2025-12-31 | -$0.03 | -$0.04 | -0.01 (-33.3%) |
| 2025-09-30 | -$0.07 | -$0.12 | -0.05 (-71.4%) |
2 ratings from 1 firm
Ratings are attributed to the research firm, not to individual analysts. Targets on listings outside the US are shown without a currency: the source does not say which one each firm used, and on cross-listed names some firms quote the US line in US dollars. See every ticker.
| Firm | Action | Rating | Price Target | Date |
|---|---|---|---|---|
| Raymond James | Maintained | Market Perform | 6.5 5 | Mar 18, 2024 |
| Raymond James | Downgraded from Outperform | Market Perform | — | Aug 6, 2021 |
94 filings from 4 insiders · 0 buy / 0 sell over 6m
Officers and directors of HLS.TO, from the last two years of filings. Grants, gifts and option exercises are shown but not colour-coded — they are compensation, not a view on the price.
| Insider | Action | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Haroun (Daniel)Senior Officer of Issuer | Other | 2.0k | $2.78 | $6k | Sep 8, 2026 |
| Hanna, John GordonDirector of Issuer | Other | 2.0k | $2.68 | $5k | Sep 1, 2026 |
| HLS Therapeutics Inc.Issuer | Other | 2.0k | $2.64 | $5k | Aug 28, 2026 |
| HLS Therapeutics Inc.Issuer | Other | 2.0k | — | — | Aug 28, 2026 |
| HLS Therapeutics Inc.Issuer | Other | 2.0k | $2.66 | $5k | Aug 27, 2026 |
| HLS Therapeutics Inc.Issuer | Other | 2.0k | — | — | Aug 27, 2026 |
| HLS Therapeutics Inc.Issuer | Other | 2.0k | $2.70 | $5k | Aug 26, 2026 |
| HLS Therapeutics Inc.Issuer | Other | 2.0k | — | — | Aug 26, 2026 |
| HLS Therapeutics Inc.Issuer | Other | 2.1k | $2.67 | $6k | Aug 25, 2026 |
| HLS Therapeutics Inc.Issuer | Other | 2.1k | — | — | Aug 25, 2026 |
| HLS Therapeutics Inc.Issuer | Other | 2.0k | $2.66 | $5k | Aug 24, 2026 |
| HLS Therapeutics Inc.Issuer | Other | 2.0k | — | — | Aug 24, 2026 |
| HLS Therapeutics Inc.Issuer | Other | 2.0k | $2.74 | $5k | Aug 21, 2026 |
| HLS Therapeutics Inc.Issuer | Other | 2.0k | — | — | Aug 21, 2026 |
| HLS Therapeutics Inc.Issuer | Other | 2.1k | $2.73 | $6k | Aug 20, 2026 |
| HLS Therapeutics Inc.Issuer | Other | 2.1k | — | — | Aug 20, 2026 |
| Millian (Craig Stuart)Director of Issuer | Other | 500 | $2.73 | $1k | Aug 20, 2026 |
| HLS Therapeutics Inc.Issuer | Other | 2.0k | $2.73 | $5k | Aug 19, 2026 |
| HLS Therapeutics Inc.Issuer | Other | 2.0k | — | — | Aug 19, 2026 |
| HLS Therapeutics Inc.Issuer | Other | 2.0k | $2.71 | $5k | Aug 18, 2026 |
Analyst Ratings
4 analysts covering
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Consensus |
|---|---|---|---|---|---|---|
| Current | 0 | 3 | 1 | 0 | 0 | Buy2.25 |
| 1 mo ago | 0 | 3 | 1 | 0 | 0 | Buy2.25 |
| 2 mo ago | 0 | 3 | 1 | 0 | 0 | Buy2.25 |
Members whose judged calls on HLS.TO have played out most reliably.
No settled calls on HLS.TO yet. 1 call is open, the first due Oct 8, 2027.
A member is listed once they have three judged calls on a name.
A call with a target is judged on whether the price reaches it by the deadline, counting each day's high (a buy) or low (a sell) from the day after the call was made. A call without one is judged on whether the price at the close on the deadline is higher (a buy) or lower (a sell) than the price the call was made at: the live price when it was saved, for a call made with Make a call, or the last close before the day it was filed, for a call made in a note. Not against the market or an index.
A percentage appears once five calls have reached their deadline. A target reached sooner is shown as played out early, and counts toward the percentage when its deadline passes, because a miss cannot be known before then.
A member’s prediction, judged on price history · not investment advice